43
Participants
Start Date
September 1, 2019
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2020
Low-Dose Naltrexone
Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
Washington University, St Louis
Washington University School of Medicine
OTHER